Testing effectiveness (Phase 2)UnknownNCT04631731
What this trial is testing
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
Who this might be right for
Lung Cancer, Nonsmall CellRenal Cell CarcinomaMelanoma+4 more
Western Sydney Local Health District 200